DXS International plc Appoints Hybridan LLP as New Corporate Adviser
DXS International plc (AQSE: DXSP), known for its cutting-edge digital clinical decision support systems, has made a significant move in its corporate strategy by selecting Hybridan LLP as its new AQSE Corporate Adviser. This strategic decision aims to enhance the company's advisory capabilities and support its growth efforts.
Importance of the Change
The decision to partner with Hybridan LLP aligns with DXS's dedication to strong corporate governance and adherence to market best practices. By collaborating with Hybridan, DXS seeks to improve its communication strategies and strengthen its presence in the market.
Influence on Corporate Strategy
With Hybridan as its adviser, DXS International plans to utilize their expertise to effectively navigate the complexities of the market. This partnership is expected to foster better engagement with investors and stakeholders, paving the way for future growth opportunities.
About DXS International
DXS International has established itself as a leader in providing real-time treatment guidelines and recommendations for healthcare professionals. By incorporating reliable information from Clinical Commissioning Groups and NHS sources into their workflows, DXS enhances the decision-making process for doctors, nurses, and pharmacists. This ultimately leads to improved healthcare outcomes, which are essential in today's fast-paced medical landscape.
Improving Healthcare Delivery
The solutions provided by DXS are not only innovative but also play a vital role in enhancing the efficiency of healthcare services. By streamlining access to crucial information during patient consultations, they help reduce costs while boosting service effectiveness.
Commitment to Excellence
As DXS begins its new partnership with Hybridan LLP, the company remains dedicated to delivering exceptional value in the healthcare sector. This change underscores DXS's commitment to innovation and excellence, solidifying its status as a leader in clinical decision support.
For any inquiries, please contact:
David Immelman
Chief Executive
DXS International plc
Email: david@dxs-systems.com
Phone: 01252 719800
Claire Louise Noyce
AQSE Stock Exchange Corporate Adviser & Corporate Broker
Hybridan LLP
Email: claire.noyce@hybridan.com
Phone: +44 20 3764 2341
Frequently Asked Questions
What is the purpose of appointing Hybridan LLP?
The appointment is intended to strengthen DXS's corporate strategy and enhance its advisory capabilities for effective market navigation.
How does DXS contribute to healthcare?
DXS enhances healthcare outcomes by providing digital clinical decision support that delivers up-to-date guidelines to healthcare professionals.
What is AQSE?
The AQSE (Aquis Stock Exchange) is a London-based stock exchange that provides a platform for trading shares in smaller, growing companies.
Who can I contact for more information?
For inquiries related to DXS International and its corporate activities, you can contact David Immelman or Claire Louise Noyce.
What is the significance of the ticker DXSP?
The ticker DXSP represents DXS International plc on the AQSE, enabling investors to track its stock performance in the market.